Free Trial

Codexis Q2 2023 Earnings Report

Codexis logo
$4.18 -0.08 (-1.88%)
As of 02/21/2025 04:00 PM Eastern

Codexis EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.04
One Year Ago EPS
-$0.04

Codexis Revenue Results

Actual Revenue
$21.32 million
Expected Revenue
$19.83 million
Beat/Miss
Beat by +$1.49 million
YoY Revenue Growth
-44.50%

Codexis Announcement Details

Quarter
Q2 2023
Time
After Market Closes

CDXS Upcoming Earnings

Codexis will be holding an earnings conference call on Thursday, February 27 at 4:30 PM Eastern. Interested parties can register for or listen to the call or dial in at 201-612-7415 using passcode "13726635".

Codexis Earnings Headlines

Codexis (CDXS) Projected to Post Quarterly Earnings on Wednesday
Codexis to Participate in TD Cowen 45th Annual Health Care Conference
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
Codexis Announces New Employment Inducement Grants
See More Codexis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Codexis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Codexis and other key companies, straight to your email.

About Codexis

Codexis (NASDAQ:CDXS) discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

View Codexis Profile

More Earnings Resources from MarketBeat